长期与单剂量挑战在青素过敏的可行性试验
Morgan Rose1,2,3, Sara Vogrin1,2, Elise A Mitri1,2,4
1Centre for Antibiotic Allergy and Research, Department of Infectious Diseases and Immunology, Austin Health, Heidelberg, VIC, Australia.
NEJM evidence
|February 24, 2026
概括
这项研究发现,一项多中心,双盲,安慰剂对照试验评估长期与单剂量阿莫西西林对青素过敏的挑战是可行的. 需要进一步的疗效试验来评估免疫介导的不良事件.
科学领域:
- 临床试验 临床试验
- 过敏和免疫学 过敏和免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 评估一项多中心,双盲,安慰剂对照试验的可行性,以挑战青素对青素过敏患者的阿莫西林.
- 评估与长期 (多剂量) 与单剂量阿莫西西林挑战相关的免疫媒介不良事件的频率.
研究的目的:
- 确定进行复杂的临床试验的可行性,涉及阿莫西西林的挑战.
- 在青素过敏群体中,探索与单剂量相比,多剂量阿莫西西林挑战的安全性和耐受性.
主要方法:
- 一个并行,双盲,安慰剂控制的多中心随机可行性试验.
- 参与研究的是具有延迟或未知时间的青素过敏史的成年人,他们可以容忍单剂量挑战.
- 参与者被随机分配到为期5天的阿莫西西林挑战或安慰剂.
主要成果:
- 120名参与者被随机分配;招募可行性为71%.
- 对干预的坚持率很高,为83%. 没有参与者需要解除盲目.
- 积极的口腔挑战发生在12%的干预组和5%的对照组中.
结论:
- 一次单剂量与多剂量口服阿莫西西林挑战的双盲,安慰剂受控随机试验是可行的.
- 需要进行全功率的疗效试验,以最终评估不同组之间的免疫媒介不良事件的差异.
相关概念视频
Allergic Reactions: Anaphylaxis
62
Anaphylaxis is a severe, life-threatening hypersensitivity reaction mediated by Immunoglobulin E (IgE) antibodies. When IgE binds to allergens, it triggers the release of mediators– histamine, leukotrienes, and prostaglandins from mast cells and basophils. These mediators cause vasodilation, edema, and inflammation, leading to various symptoms.The primary allergens causing anaphylaxis include food items (e.g., peanuts, shellfish), drugs (e.g., penicillin, asparaginase, corticotropin,...
62
Allergic Reactions
32.6K
Overview
32.6K
Bioavailability Study Design: Single Versus Multiple Dose Studies
283
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
283
Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration
38
Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms for excretion, typically via enzymatic processes classified as phase I (modification) and phase II (conjugation). Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys. Impairment in liver or kidney function can hinder these processes, delaying drug clearance and extending the drug’s...
38


